Markers of exacerbation severity in chronic obstructive pulmonary disease

被引:52
作者
Franciosi, Luigi G. [1 ]
Page, Clive P.
Celli, Bartolome R.
Cazzola, Mario
Walker, Michael J.
Danhof, Meindert
Rabe, Klaus F.
Della Pasqua, Oscar E.
机构
[1] Leiden Univ, Leiden Amsterdam Ctr Drug Res, Leiden, Netherlands
[2] Kings Coll London, Sackler Inst Pulm Pharmacol, London WC2R 2LS, England
[3] Tufts Univ, St Elizabeths Hosp, Boston, MA 02111 USA
[4] A Cardarelli Hosp, Dept Resp Med, Naples, Italy
[5] Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1W5, Canada
[6] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands
[7] GlaxoSmithKline, Clin Pharmacol & Discovery Med, Greenford, Middx, England
关键词
D O I
10.1186/1465-9921-7-74
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Patients with chronic obstructive pulmonary disease ( COPD) can experience 'exacerbations' of their conditions. An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management. There is a need for reliable markers that reflect the pathological mechanisms that underlie exacerbation severity and that can be used as a surrogate to assess treatment effects in clinical studies. Little is known as to how existing study variables and suggested markers change in both the stable and exacerbation phases of COPD. In an attempt to find the best surrogates for exacerbations, we have reviewed the literature to identify which of these markers change in a consistent manner with the severity of the exacerbation event. Methods: We have searched standard databases between 1966 to July 2004 using major keywords and terms. Studies that provided demographics, spirometry, potential markers, and clear eligibility criteria were included in this study. Central tendencies and dispersions for all the variables and markers reported and collected by us were first tabulated according to sample size and ATS/ERS 2004 Exacerbation Severity Levels I to III criteria. Due to the possible similarity of patients in Levels II and III, the data was also redefined into categories of exacerbations, namely out-patient ( Level I) and in-patient ( Levels II & III combined). For both approaches, we performed a fixed effect meta-analysis on each of the reported variables. Results: We included a total of 268 studies reported between 1979 to July 2004. These studies investigated 142,407 patients with COPD. Arterial carbon dioxide tension and breathing rate were statistically different between all levels of exacerbation severity and between in out- and in-patient settings. Most other measures showed weak relationships with either level or setting, or they had insufficient data to permit meta-analysis. Conclusion: Arterial carbon dioxide and breathing rate varied in a consistent manner with exacerbation severity and patient setting. Many other measures showed weak correlations that should be further explored in future longitudinal studies or assessed using suggested mathematical modelling techniques.
引用
收藏
页数:14
相关论文
共 58 条
  • [1] Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease
    Aaron, SD
    Vandemheen, KL
    Hebert, P
    Dales, R
    Stiell, IG
    Ahuja, J
    Dickinson, G
    Brison, R
    Rowe, BH
    Dreyer, J
    Yetisir, E
    Cass, D
    Wells, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) : 2618 - 2625
  • [2] *AG HEALTHC RES QU, 2000, MAN AC EX CHRON OBST
  • [3] ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
    ANTHONISEN, NR
    MANFREDA, J
    WARREN, CPW
    HERSHFIELD, ES
    HARDING, GKM
    NELSON, NA
    [J]. ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) : 196 - 204
  • [4] Bacteria and exacerbations of chronic obstructive pulmonary disease
    Anthonisen, NR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 526 - 527
  • [5] Armitage P., 2001, STAT METHODS MED RES, V4th
  • [6] Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial
    Ayres, JG
    Price, MJ
    Efthimiou, J
    [J]. RESPIRATORY MEDICINE, 2003, 97 (03) : 212 - 220
  • [7] Management of acute exacerbations of chronic obstructive pulmonary disease: A summary and appraisal of published evidence
    Bach, PB
    Brown, C
    Gelfand, SE
    McCrory, DC
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) : 600 - 620
  • [8] Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease
    Barbera, JA
    Roca, J
    Ferrer, A
    Felez, MA
    Diaz, O
    Roger, N
    RodriguezRoisin, R
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (06) : 1285 - 1291
  • [9] Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations
    Bhowmik, A
    Seemungal, TAR
    Sapsford, RJ
    Wedzicha, JA
    [J]. THORAX, 2000, 55 (02) : 114 - 120
  • [10] COPD exacerbations: definitions and classifications
    Burge, S
    Wedzicha, JA
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 21 : 46S - 53S